Spleen Removal (Splenectomy) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Splenectomy is the surgical removal of the spleen — a fist-sized, highly vascular organ located in the left upper quadrant of the abdomen beneath the lower rib cage. The spleen performs two principal physiological functions: immunological filtration (removing aged or abnormal red blood cells, platelets, and blood-borne pathogens, particularly encapsulated bacteria) and immune surveillance (harbouring specialised B-lymphocytes and macrophages that mount rapid antibody responses to novel antigens). These functions make the spleen central to both haematological homeostasis and innate immunity.

Splenectomy has been performed since the late 19th century and remains one of the more frequently performed abdominal operations in general and haematological surgery. The introduction of laparoscopic techniques in the 1990s transformed the procedure: the minimally invasive approach is now the standard of care for most elective splenectomies, offering faster recovery, reduced blood loss, lower wound infection rates, and equivalent safety compared to traditional open surgery.

The consequences of spleen removal are permanent and significant. Asplenic (without a spleen) individuals are at lifelong risk of overwhelming post-splenectomy infection (OPSI) — a rare but potentially fatal condition caused by encapsulated bacteria (primarily Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis) that the absent spleen would normally clear rapidly. This risk mandates structured vaccination protocols, patient education, and in many guidelines, prophylactic antibiotic use, particularly in the first 2 years after splenectomy.

The decision to perform splenectomy must therefore carefully weigh the surgical benefit against the lifelong infectious risk, and wherever possible, the minimum effective surgical procedure (including partial splenectomy in children with hereditary haemolytic conditions) should be pursued.

Splenectomy is indicated across a range of haematological, traumatic, vascular, and oncological conditions:

• Immune Thrombocytopenic Purpura (ITP): The most common elective indication in adults. In ITP, autoantibodies (primarily anti-platelet IgG) coat platelets, which are then recognised and destroyed by splenic macrophages. Splenectomy eliminates both the major site of platelet destruction and a significant source of anti-platelet antibody production. Complete platelet count response (greater than 100 x 10⁹/L) is achieved in approximately 60–70% of patients; response is durable at 5 years in 50–60%.
• Hereditary Spherocytosis (HS): A congenital red cell membrane defect causing chronic haemolytic anaemia and splenomegaly. The abnormal spherocytic red cells are selectively trapped and destroyed in the spleen. Splenectomy eliminates haemolysis in virtually all patients with HS, curing the anaemia. Partial splenectomy is preferred in children to preserve some immunological function.
• Thalassaemia Major: Severe transfusion-dependent thalassaemia leads to massive splenomegaly and secondary hypersplenism (increased red cell and platelet destruction). Splenectomy reduces transfusion requirements and may improve quality of life, though it does not alter the underlying haemoglobin defect.
• Sickle Cell Disease: Autoinfarction of the spleen is common in sickle cell disease and may lead to acute splenic sequestration — a life-threatening trapping of red cells in the spleen causing sudden profound anaemia. Emergency or elective splenectomy is indicated after a first or second sequestration crisis in young children.
• Splenic Trauma: High-grade splenic lacerations (AAST Grade IV–V) causing haemodynamic instability not amenable to non-operative or angioembolisation management require urgent splenectomy. Non-operative management and angioembolisation have substantially reduced the rate of trauma splenectomy in haemodynamically stable patients.
• Hypersplenism: Pathological overactivity of the spleen causing pancytopenia (reduction in red cells, white cells, and platelets) secondary to portal hypertension, storage disorders (Gaucher disease), or haematological malignancy.
• Splenic Abscess and Vascular Lesions: Splenic abscess refractory to antibiotics and percutaneous drainage, splenic artery aneurysm (greater than 2 cm or symptomatic), and symptomatic splenic cysts may require splenectomy.

Pre-operative assessment for splenectomy is directed by the underlying indication and the planned surgical approach:

For ITP: Guidelines from the American Society of Hematology (ASH) recommend splenectomy after failure of first-line corticosteroid therapy and a structured trial of second-line agents including rituximab and thrombopoietin receptor agonists (TPO-RAs: eltrombopag, romiplostim). Predictors of good surgical response include: younger age, short disease duration, good initial response to corticosteroids, and positive indium-111 scintigraphy demonstrating predominantly splenic platelet sequestration (though this investigation is not universally required).

For hereditary haemolytic anaemias: Splenectomy is most clearly indicated when transfusion dependency, gallstone formation, or growth failure is present. The optimal age for surgery is debated — delaying beyond age 5–6 years preserves early childhood immune responses while reducing the risk of severe haemolysis. Vaccination should precede elective surgery by at least 2 weeks.

Spleen size: Laparoscopic splenectomy is feasible for spleens up to approximately 20 cm in length (massive splenomegaly). Beyond this size, hand-assisted laparoscopic or open approaches are generally preferred to avoid uncontrolled splenic bleeding from a grossly enlarged, friable organ.

Haematological optimisation: Platelet count should ideally exceed 20–30 x 10⁹/L for safe surgery; pre-operative platelet transfusion, IV immunoglobulin (IVIG), or high-dose corticosteroids may be administered immediately before surgery to achieve this. Pre-operative treatment with IVIG typically raises platelet count within 48–72 hours and is standard practice before splenectomy in severe ITP.

Vaccination: At least 2 weeks before elective surgery, patients must receive vaccines against S. pneumoniae (conjugate + polysaccharide), H. influenzae type b, and N. meningitidis (serogroups A, C, W, Y and B). If urgent surgery prevents pre-operative vaccination, vaccines are administered at least 2 weeks post-operatively (sufficient immune recovery typically occurs by 2 weeks post-operatively in most patients).

The choice of surgical approach is guided by spleen size, urgency, patient body habitus, and surgeon expertise:

• Laparoscopic Splenectomy (Standard Elective Approach): Three to four small (5–12 mm) port incisions in the left abdomen allow insertion of a camera and instruments under CO₂ insufflation. The spleen is mobilised by dividing its ligamentous attachments, the splenic hilum (containing the splenic artery and vein) is secured with a laparoscopic stapler or vascular clips, and the spleen is extracted in a bag through a slightly enlarged port incision. Operative time: 1–2 hours. Hospital stay: 1–2 days. Advantages include minimal incision, low infection rate, faster recovery, and superior cosmesis.
• Hand-Assisted Laparoscopic Splenectomy (HALS): A hand-port device allows the surgeon to insert one hand into the abdomen while maintaining pneumoperitoneum. Useful for moderately enlarged spleens (15–25 cm) where tactile feedback and direct manual control of haemorrhage are advantageous. Bridges the gap between laparoscopic and open surgery.
• Open Splenectomy: A left subcostal (Kocher's) or midline laparotomy provides wide access. Indicated for haemodynamically unstable trauma, massively enlarged spleens, dense perisplenic adhesions from prior surgery, or oncological resection requiring en-bloc removal. Longer recovery (5–7 days hospital stay, 4–6 weeks return to activity) and higher wound complication rates compared to laparoscopic approaches.
• Partial Splenectomy: Removal of only the lower pole or a defined segment of the spleen, preserving the upper pole with its immunological tissue. Particularly recommended in children with hereditary spherocytosis, thalassaemia, and storage disorders where some splenic immune function is desirable. Technically demanding due to bleeding risk from the splenic parenchyma, but preserves humoral immunity and reduces OPSI risk.
• Splenic Artery Embolisation (SAE): Interventional radiology technique in which particulate material is injected into the splenic artery to infarct a proportion of splenic tissue. Used as an alternative to splenectomy in haemodynamically stable trauma, as a pre-operative adjunct to reduce intraoperative bleeding in massive splenomegaly, and in patients with portal hypertension-related hypersplenism who are too high-risk for surgery.

The benefits of splenectomy are condition-specific and generally substantial when the indication is well-established:

• ITP: Complete platelet response (greater than 100 x 10⁹/L) in 60–70% of patients; partial response (greater than 30 x 10⁹/L with doubling from baseline) in an additional 10–15%. Durable response at 5 years in 50–60%. Splenectomy remains the only treatment for ITP with the potential for long-term, treatment-free remission. Systematic reviews and ASH guidelines rank it as a second-line treatment after rituximab and TPO-RAs due to the infectious risk.
• Hereditary Spherocytosis: Splenectomy virtually eliminates haemolysis in all patients with HS. Reticulocyte counts, haemoglobin, and bilirubin normalise within days to weeks of surgery. The risk of pigment gallstones (a complication of chronic haemolysis) is eliminated. Growth and development normalise in children.
• Thalassaemia: Splenectomy reduces the transfusion burden by 25–50% in transfusion-dependent patients with massive hypersplenism, reducing iron overload and its long-term cardiac and hepatic consequences.
• Trauma: Emergency splenectomy is life-saving in uncontrolled haemorrhage from high-grade splenic injury that cannot be controlled by less invasive means.
• Symptomatic splenomegaly: Removal of a massively enlarged, painful spleen provides immediate symptomatic relief of left-sided abdominal pain, early satiety, and shoulder discomfort.
• Hypersplenism: Correction of pancytopenia allows reduction or cessation of growth factor therapy and transfusion support, and may enable more aggressive treatment of the underlying haematological malignancy.

Splenectomy carries both operative and lifelong post-operative risks that must be central to the informed consent process:

• Overwhelming Post-Splenectomy Infection (OPSI): The most important long-term risk. OPSI is a fulminant septicaemia caused primarily by encapsulated bacteria — Streptococcus pneumoniae (responsible for approximately 50% of OPSI cases), H. influenzae type b (25%), and N. meningitidis (10–15%). It presents as a rapidly deteriorating febrile illness that can progress to septic shock and death within 24–48 hours. Lifetime incidence after splenectomy: approximately 0.5–5% depending on underlying disease and vaccination status. Mortality of established OPSI: 30–70%. Risk is highest in the first 2 years post-splenectomy and in children under 5 years. This underscores the critical importance of vaccination, antibiotic prophylaxis, and patient education (patients carry an antibiotic emergency card and take antibiotics immediately on developing a fever).
• Reactive Thrombocytosis: Platelet counts frequently rise substantially (sometimes exceeding 1,000 x 10⁹/L) in the weeks following splenectomy as the splenic platelet reservoir is lost. This post-splenectomy thrombocytosis is usually transient and self-limiting, but carries a risk of venous thromboembolism, particularly in patients with underlying myeloproliferative conditions. Low-dose aspirin is often prescribed.
• Subphrenic Abscess: Collection of infected fluid in the space left by the removed spleen. Presents with fever, left upper quadrant pain, and left pleural effusion at 5–10 days post-operatively. Managed with image-guided drainage.
• Pancreatic Tail Injury: The pancreatic tail lies in close proximity to the splenic hilum; inadvertent injury causes post-operative pancreatitis or pancreatic fistula in approximately 1–3% of cases. Usually managed conservatively.
• Haemorrhage: Intraoperative bleeding from the fragile splenic hilum is the most common reason for conversion from laparoscopic to open surgery (conversion rate approximately 5–10%). Post-operative haemorrhage is uncommon (less than 1%) but may require re-operation or angioembolisation.
• Venous Thromboembolism: Prolonged operative time, immobility, and reactive thrombocytosis increase the risk of DVT and pulmonary embolism. Mechanical and pharmacological prophylaxis is standard, and VTE risk is highest in the 4–6 weeks following surgery.
• Wound complications: Port site hernia (0.5–2% for laparoscopic), wound infection, and haematoma at extraction site. Conversion to open surgery carries the higher wound complication rate of laparotomy.

Post-splenectomy care is lifelong and uniquely combines surgical recovery with ongoing infection prevention:

Immediate post-operative recovery: Laparoscopic splenectomy: hospital stay 1–2 days, return to light activities 1–2 weeks, return to full activity 3–4 weeks. Open splenectomy: hospital stay 4–7 days, return to full activity 6–8 weeks. Driving restrictions of 1–2 weeks (laparoscopic) and 4–6 weeks (open) are standard.

Vaccination protocol: This is the single most important protective measure against OPSI. For patients not vaccinated pre-operatively, vaccination is administered at least 2 weeks post-splenectomy to allow sufficient immune reconstitution:

• Pneumococcal: 13-valent conjugate vaccine (PCV13) followed by 23-valent polysaccharide vaccine (PPSV23) at 8 weeks, then booster PPSV23 every 5 years.
• Haemophilus influenzae type b (Hib): Single dose if not previously vaccinated.
• Meningococcal: MenACWY conjugate vaccine (with booster every 5 years) plus MenB vaccine.
• Annual influenza vaccination (reduces secondary bacterial pneumonia risk).

Antibiotic prophylaxis: Phenoxymethylpenicillin (penicillin V) 250–500 mg twice daily is recommended for at least 2 years post-splenectomy in all adults, and lifelong in children under 16 and in high-risk patients (underlying haematological malignancy, poor vaccination response, prior OPSI episode). Erythromycin or amoxicillin are used in penicillin-allergic individuals.

Patient education: Every asplenic patient must understand: (1) to seek immediate medical attention and start stand-by antibiotics (amoxicillin 3 g stat or prescribed emergency supply) at the first sign of fever or systemic illness; (2) to inform all future treating clinicians of their asplenic status; (3) to carry a medical alert card/bracelet; (4) the risks of tick bites (Babesia), dog bites (Capnocytophaga), and malaria in endemic travel regions (prompt prophylaxis essential).

Haematological follow-up: Platelet counts monitored at 1, 4, and 12 weeks post-operatively to identify extreme thrombocytosis requiring antiplatelet therapy. ITP patients require ongoing haematology review even after successful splenectomy, as late relapse (beyond 5 years) occurs in 15–25% of initial responders.

Splenectomy costs vary by approach (laparoscopic vs open), urgency, spleen size, and underlying indication:

• Laparoscopic elective splenectomy (ITP, hereditary spherocytosis): United States: USD 25,000–55,000 (including hospital, surgery, and anaesthesia). United Kingdom (NHS): covered for medically indicated cases; private: GBP 8,000–15,000. India, Thailand, Turkey: USD 3,500–7,000 all-inclusive.
• Open splenectomy (massive splenomegaly): Higher cost due to longer operative time, larger incision, greater blood product use, and longer hospital stay. US: USD 35,000–70,000. Medical tourism: USD 5,000–12,000.
• Emergency trauma splenectomy: Emergency department charges, ICU stay, blood products, and longer hospital stay substantially increase cost. Total episode cost in US trauma centres: USD 60,000–120,000.
• Vaccination cost: The complete vaccination schedule (pneumococcal conjugate, polysaccharide, Hib, meningococcal ACWY, meningococcal B) costs USD 400–800 in the US. Most national health systems provide these vaccines free of charge for asplenic patients.
• Ongoing antibiotic prophylaxis: Generic penicillin V is inexpensive (USD 5–15 per month). The long-term cost is negligible compared to the cost of treating OPSI.

For patients considering medical tourism, key considerations specific to splenectomy include the availability of haematology support for peri-operative platelet management in ITP, an experienced laparoscopic surgical team with skills in managing splenic bleeding, and the ability to receive post-operative vaccinations before leaving the host country or through a pre-planned schedule in the home country.

The decision to remove the spleen is increasingly preceded by trials of spleen-preserving or non-surgical alternatives, particularly given the lifelong infectious risks of asplenia:

• For ITP — Thrombopoietin Receptor Agonists (TPO-RAs): Romiplostim (subcutaneous weekly injection) and eltrombopag (daily oral tablet) stimulate platelet production and maintain safe platelet counts in the majority of ITP patients, deferring or replacing splenectomy. Sustained remission after TPO-RA discontinuation occurs in 10–30% of patients. Recommended as second-line therapy before splenectomy by current ASH guidelines.
• For ITP — Rituximab: Anti-CD20 monoclonal antibody depletes pathological B-lymphocytes producing anti-platelet antibodies. Complete response in 40–60% of patients initially; durable response at 5 years in only 20–25%. Avoids splenectomy in a subset of patients, particularly those with a good initial rituximab response.
• For ITP — Fostamatinib and Avatrombopag: Newer approved agents for chronic refractory ITP that may reduce the need for splenectomy as further alternatives accumulate evidence.
• For Hereditary Haemolytic Anaemias — Partial Splenectomy: Removes the majority of the splenic mass responsible for haemolysis while preserving immunological residual tissue. Increasingly preferred in children with HS and thalassaemia where preservation of even partial splenic immune function substantially reduces OPSI risk.
• For Trauma — Non-Operative Management (NOM) and Angioembolisation: The shift toward splenic preservation in trauma has been dramatic. Haemodynamically stable patients with splenic lacerations (AAST Grades I–III and selected Grade IV) are managed non-operatively with bed rest and serial imaging. Angiographic embolisation of bleeding splenic vessels achieves haemostasis in 70–90% of appropriately selected patients, avoiding splenectomy entirely and preserving splenic function.
• For Hypersplenism — Splenic Artery Embolisation: Partial embolisation of the splenic artery infarcts a controlled proportion of splenic parenchyma, reducing hypersplenic effects (thrombocytopenia, neutropenia) without total splenectomy. Used in portal hypertension-related hypersplenism and in high-surgical-risk patients.